The Expressions of Wnt/β-catenin Pathway-Related Components in Brainstem Gliomas

Wenhao Wu, Yongji Tian, Hong Wan, Yongmei Song, Junhua Li, Liwei Zhang

**ABSTRACT: Background:** The overall prognosis of brainstem gliomas is very poor, and the current treatment cannot significantly prolong the overall survival of these patients; therefore, studying the molecular biological mechanisms of the occurrence and development of brainstem gliomas has important significance for their treatment. The Wnt/β-catenin signaling pathway is closely associated with the occurrence and development of tumors, but its relationship with brainstem gliomas remains unclear. **Methods:** This study used Western blot and immunohistochemistry methods to detect the expressions of Wnt/β-catenin signaling pathway-related components such as Wnt-1, Wnt-2, β-catenin and C-myc in six cases of normal brain tissues and 24 cases of brainstem gliomas and analyzed the relationship between their expressions and clinicopathological characteristics. **Results:** Wnt-1 had no obvious expression in normal brain tissues and did not show any significant difference between high- and low-grade brainstem gliomas; the expressions of Wnt-2, β-catenin and C-myc in high-grade brainstem gliomas were significantly higher than that in low-grade brainstem gliomas and normal brain tissues and were positively correlated with the expression of Ki-67. Moreover, the expressions of Wnt-2 and C-myc were significantly associated with the prognosis of brainstem glioma patients; additionally, there was a trend toward increased β-catenin expression with shorter survival, but there was no statistical difference. **Conclusions:** Wnt/β-catenin signaling pathway might be abnormally activated and plays an important role in the occurrence and development of brainstem gliomas. Wnt-2, β-catenin and C-myc may be potential targets for brainstem glioma treatment.

**RÉSUMÉ: Expression de composantes reliées à la voie de signalisation Wnt/β-caténine dans les gliomes du tronc cérébral. Contexte : Le pronostic général des gliomes du tronc cérébral est très mauvais et le traitement actuel ne prolonge pas significativement la survie de ces patients. Il est donc important d’étudier les mécanismes de biologie moléculaire liés à leur apparition et à leur développement afin d’en améliorer le traitement. La voie de signalisation Wnt/β-caténine est étroitement associée à l’apparition et au développement de tumeurs. Cependant, on ignore sa relation aux gliomes du tronc cérébral. **Méthode :** Dans cette étude, nous avons utilisé le buvardage Western ainsi que des méthodes d’immunohistochimie pour détecter l’expression de composantes reliées à la voie de signalisation Wnt/β-caténine, telles Wnt-1, Wnt-2, β-caténine et C-myc, dans 6 cerveaux normaux et 24 gliomes du tronc cérébral et nous avons analysé la relation entre leur expression et les caractéristiques anatomo-cliniques des tumeurs. **Résultats :** Wnt-1 n’avait pas d’expression apparente dans les tissus cérébraux normaux et il n’y avait pas de différence significative entre les gliomes du tronc cérébral de haut grade et ceux de bas grade de malignité. L’expression de Wnt-2, de β-caténine et de C-myc dans les gliomes du tronc cérébral de haut grade était significativement plus élevée que dans ceux de bas grade et dans le tissu cérébral normal, et leur expression était corrélée de façon positive à l’expression de Ki-67. De plus, l’expression de Wnt-2 et de C-myc était associée de façon significative au pronostic des patients atteints de gliomes du tronc cérébral. Une expression augmentée de β-caténine avait tendance à être associée à une survie plus courte, mais la différence n’était pas significative au point de vue statistique. **Conclusions :** Il se peut que la voie de signalisation Wnt/β-caténine soit activée de façon anormale et joue un rôle important dans l’apparition et le développement des gliomes du tronc cérébral. Wnt-2, β-caténine et C-myc pourraient constituer des cibles de traitement du gliome du tronc cérébral.
with Capital Medical University, performs approximately 20
brainstem glioma surgeries each year. This provides
opportunities to conduct molecular biological studies of
brainstem gliomas.

The abnormal activation of Wnt/β-catenin signaling pathway
is closely associated with the occurrence and development of
many human tumors. Recently, target therapies through
interference or blocking of Wnt/β-catenin signaling pathway to
observe whether the tumor progression can be blocked or
delayed have become a major focus of tumor research.3-5
However, the relationship between Wnt/β-catenin signaling
pathway and gliomas, especially brainstem gliomas, remains
unclear. In this study, we use Western blot and immuno-
histochemistry methods to detect the expression of the
components involved in Wnt/β-catenin signaling pathway, such as
Wnt-1, Wnt-2, β-catenin and the downstream target gene C-
myc, in brainstem gliomas to explore the relationship between
their occurrence, development and prognosis and the Wnt/β-
catenin signaling pathway to provide a molecular basis for future
target therapies of brainstem glioma.

MATERIALS AND METHODS

Tissue samples

With Institutional Review Board approval, freshly resected
brainstem glioma samples were obtained from Beijing Tiantan
Hospital and then stored in liquid nitrogen prior to use. None of
the patients had been subjected to radiotherapy and/or
chemotherapy prior to surgery. According to the World Health
Organization classification (WHO 2007), the tumors were
pathologically classified as low grade (WHO I-II) or high grade
(WHO III-IV). The histological subtypes and pathologic grades
of all brainstem glioma samples, which were confirmed by two
pathologists independently, are given in Table 1. A total of 24
cases of tumor samples, including 16 low-grade brainstem
gliomas and eight high-grade gliomas, were collected for this
study. There were 14 males and 10 females, varying in age from
3 to 64 years (average 27.3 years). The tumors were located at
midbrain in six cases, at pons in nine cases, and medulla nine
cases. Non-neoplastic brain tissues from six patients with
intractable epilepsy were also included as controls. Clinical data
of the patients were collected and follow-up of all the patients
was performed. Before enrollment, each patient in this study
signed a written informed consent.

Western blot

Frozen samples were ground in liquid nitrogen and were
homogenized in lysis buffer [phosphate buffered saline (PBS),
50 mM Tris, 150 mM NaCl, 1% nonidet P-40 (NP-40), 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 2
µg/ml aprotinin, 50 µg/ml phenylmethylsulfonyl fluoride
(PMSF)], then incubated on ice for 30 minutes (min), followed
by centrifugation at 12 000 rpm for 20 min at 4°C. The protein
content was determined according to Bradford’s method, using
bovine serum albumin as a standard. Protein samples were
separated by size on 10% polyacrylamide gel under SDS
denaturing conditions, and transferred onto a polyvinylidene
difluoride membrane at 12 V for 2 hours (h). The membrane was
blocked in 5% non-fat milk and incubated with primary antibody
against Wnt-1, Wnt-2, β-catenin and C-myc (1:300, 1:200, 1:500
and 1:500 dilution, respectively) overnight at 4°C. The
membranes were then covered with horseradish peroxidase-
conjugated secondary antibody for one hour at room
temperature. Detection was performed using an enhanced
chemiluminescence method. β-actin was used as a loading
control. Positive immunoreactive bands were quantified
densitometrically and expressed as ratio of the above mentioned
proteins to β-actin in optical density units.

Immunohistochemistry

With a cryostat, 6 µm sections were cut and then air-dried.
Sections were fixed with acetone at 4°C for ten minutes.
Endogenous peroxidase activity and non-specific staining were
blocked with a 3% hydrogen peroxide-methanol solution and
normal goat serum, respectively. Sections were then incubated
with primary antibodies overnight at 4°C in a humidified
chamber. The primary antibodies against Wnt-1 (rabbit
polyclonal antibody, Abcam, Cambridgeshire, UK), Wnt-2 (goat
polyclonal antibody, R&D, Minnesota, USA) and C-myc (mouse
monoclonal antibody, Santa Cruz, California, USA) were diluted
to 1:50, 1:20 and 1:50, respectively. The anti-β-catenin and anti-
Ki-67 antibody (mouse monoclonal antibody, Millipore,
Massachusetts, USA) were used at a 1:60 and 1:100 dilution.
Secondary antibodies were reacted for 1 h at room temperature.
The sections were then incubated in a streptavidin-avidin
complex labeled by horseradish peroxidase and developed using
diaminobenzidine. Next, the sections were counterstained with
hematoxylin, dehydrated in alcohol and xylene and covered with
coverslips. In each immunostaining, PBS was used instead of the
primary antibody to serve as a negative control. The expression
levels of Wnt-1, Wnt-2, β-catenin and C-myc in each sample
were scored according to the percentage of positive staining cells
in at least five high-magnification fields: 0: <1% positive cells,
1: 1-10% positive cells, 2: 10-25% positive cells, 3: 25-50%
positive tumor cells, 4: positive cell ratio >50%. Ki-67 positive
cells in each section were counted for label indexing. The
percentage of Ki-67-positive cells among 103 tumor cells were
calculated and statistically compared. The staining was scored in
an investigator-blinded fashion.

Table 1: Histologic subtypes and pathologic grades of human
brainstem glioma samples

<table>
<thead>
<tr>
<th>Pathological diagnosis</th>
<th>WHO grade</th>
<th>Sample size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ganglioglioma</td>
<td>I</td>
<td>2</td>
</tr>
<tr>
<td>Diffuse astrocytoma</td>
<td>II</td>
<td>11</td>
</tr>
<tr>
<td>Oligoastrocytoma</td>
<td>II</td>
<td>3</td>
</tr>
<tr>
<td>Anaplastic ependymoma</td>
<td>III</td>
<td>1</td>
</tr>
<tr>
<td>Anaplastic astrocytoma</td>
<td>III</td>
<td>3</td>
</tr>
<tr>
<td>Glioblastoma</td>
<td>IV</td>
<td>4</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>24</td>
</tr>
</tbody>
</table>
All data were expressed as the means ± standard deviation. Analyses were performed using the statistical software package SPSS 17.0. A one-way analysis of variance (ANOVA) test was used to analyze the expression levels of brainstem gliomas and controls. The differences among clinicopathological variables in different groups were analyzed by the Student t-test or Wilcoxon test. Kaplan–Meier survival curves were generated, and differences in overall survival were compared using the log-rank test. *P* <0.05 was considered significant.

**Results**

**The expressions of Wnt-1, Wnt-2, β-catenin and C-myc by Western blot**

The expressions of Wnt-1, Wnt-2, β-catenin and C-myc were detected in six cases of normal brain tissues, 16 cases of low-grade brainstem gliomas, and eight cases of high-grade brainstem gliomas using Western blot analysis. The results of this semi-quantitative analysis show that Wnt-1 expression in brainstem gliomas was significantly higher than that in normal brain tissues (*P* <0.05), and its expression did not show any significant difference between high- and low-grade brainstem gliomas (*P* >0.05); Wnt-2, β-catenin and C-myc all had different levels of expression in normal brain tissues and brainstem gliomas, and their expressions in high-grade brainstem gliomas were significantly higher than that in low-grade brainstem gliomas and normal brain tissues (*P* <0.05; Figure 1).

**Immunohistochemical staining of Wnt-1, Wnt-2, β-catenin, C-myc and Ki-67**

There was no obvious staining of Wnt-1 in normal brain tissues, but it was expressed in some brainstem gliomas and...
localized to the cell membrane or juxtamembrane regions of the cytoplasm. Wnt-2 was expressed in both normal brain tissues and brainstem gliomas and had a similar location to Wnt-1 in the cell. β-catenin was expressed in the cell membrane or juxtamembrane region of the cytoplasm in normal brain tissues, and in the cytoplasm in brainstem gliomas; there was no significant positive nuclear expression. C-myc was localized in the nucleus and expressed in normal brain tissues and brainstem gliomas to different degrees. Ki-67 was not expressed in normal brain tissues, and its expression in brainstem gliomas was significantly correlated with pathological grades and positively correlated with the expressions of Wnt-2, β-catenin and C-myc (r=0.455, r=0.730, r=0.610, respectively; P<0.05; Figure 2).

Association of Wnt-1, Wnt-2, β-catenin and C-myc immunohistochemical expressions with clinicopathological characteristics

The expressions of Wnt-1, Wnt-2, β-catenin and C-myc did not show any statistical differences regarding sex, age, and tumor location. The expression of Wnt-1 in high- and low-grade brainstem gliomas did not show significant difference (P>0.05), while the expressions of Wnt-2, β-catenin and C-myc in high-grade brainstem gliomas were significantly higher than that in low-grade brainstem gliomas (P<0.05); these results were consistent with the Western blot data (Table 2). Furthermore, the results obtained from the survival analysis show that Wnt-1 and β-catenin expressions were not significantly correlated with the overall survival of brainstem gliomas (P>0.05); however, there was a trend toward increased β-catenin expression with decreased overall survival; the expressions of Wnt-2 and C-myc were significantly associated with the survival time; the survival of the low-expression group was significantly longer than that of the high-expression group (P<0.05; Figure 3).

DISCUSSION

Gliomas are the most common intracranial malignant tumors, and gliomas in different locations can have different clinical treatment efficacies and prognosis. The overall survival of patients with cerebral hemisphere gliomas can be significantly prolonged through comprehensive treatments such as surgery, radiotherapy and chemotherapy, but the survival of patients with brainstem gliomas usually cannot. Brainstem gliomas account for 1.5-2.5% of adult brain tumors and 10-20% of childhood brain tumors.1 Although the incidence of brainstem gliomas is not high compared to cerebral hemisphere gliomas, the overall prognosis is poorer, and these tumors severely affect the survival and neurological functions of patients. There are strict indications for brainstem glioma surgery, and a majority of patients are not suitable for operation;6,7 radiotherapy usually can only achieve temporary improvement of the symptoms, but cannot prolong survival, and there is currently no precise and effective chemotherapy treatment;8,9 thus, there is no mature therapy regimen to significantly improve the clinical prognosis of most brainstem glioma patients. The differences of clinical treatment efficacy between brainstem gliomas and cerebral hemisphere gliomas might be due to the specific location of the brainstem; what’s more, there are far more studies concerning the molecular biology and translational medicine of cerebral hemisphere gliomas compared to brainstem gliomas. Under the same pathological nature and treatment methods, the treatment efficacies of cerebral hemisphere gliomas and brainstem gliomas are different, indicating that brainstem gliomas might represent a group of tumors with unique biological features. It is a developing trend to understand tumors including brainstem gliomas from the molecular level to explore the mechanism of their occurrence and development and search for more targeted clinical treatment methods. Unfortunately, due to the limitation of specimen, there are fewer basic studies concerning brainstem gliomas.

Table 2: Wnt-1, Wnt-2, β-catenin and C-myc expression levels in human brainstem gliomas with clinicopathological characteristics

<table>
<thead>
<tr>
<th>Variables</th>
<th>n</th>
<th>Score for Wnt-1 expression</th>
<th>Score for Wnt-2 expression</th>
<th>Score for β-catenin expression</th>
<th>Score for C-myc expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;18</td>
<td>11</td>
<td>0.82±0.87</td>
<td>1.55±0.82</td>
<td>1.64±0.92</td>
<td>1.36±0.67</td>
</tr>
<tr>
<td>≥18</td>
<td>13</td>
<td>1.38±1.04</td>
<td>1.62±0.77</td>
<td>1.62±0.77</td>
<td>1.62±0.51</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>14</td>
<td>1.07±1.00</td>
<td>1.57±0.76</td>
<td>1.64±0.84</td>
<td>1.43±0.51</td>
</tr>
<tr>
<td>Female</td>
<td>10</td>
<td>1.20±1.03</td>
<td>1.60±0.84</td>
<td>1.60±0.84</td>
<td>1.60±0.70</td>
</tr>
<tr>
<td>Pons</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>9</td>
<td>1.33±1.00</td>
<td>2.00±0.71</td>
<td>1.67±0.87</td>
<td>1.78±0.44</td>
</tr>
<tr>
<td>No</td>
<td>15</td>
<td>1.00±1.00</td>
<td>1.33±0.72</td>
<td>1.60±0.83</td>
<td>1.33±0.62</td>
</tr>
<tr>
<td>WHO grade</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>16</td>
<td>1.06±0.93</td>
<td>1.38±0.81*</td>
<td>1.44±0.89*</td>
<td>1.31±0.60*</td>
</tr>
<tr>
<td>High</td>
<td>8</td>
<td>1.25±1.16</td>
<td>2.00±0.53</td>
<td>2.00±0.53</td>
<td>1.88±0.35</td>
</tr>
</tbody>
</table>

*compared to high-grade brainstem gliomas, P<0.05; WHO=World Health Organization
The overall survival of patients with low Wnt-2 expression was obviously between Wnt-1 expression and overall survival of patients (P>0.05); (b) 2, β-catenin and C-myc. (a) There was no significant association brainstem glioma patients with low and high expressions of Wnt-1, Wnt-

Figure 3: Kaplan–Meier survival curves of the overall survival of brainstem glioma patients with low and high expressions of Wnt-1, Wnt-2, β-catenin and C-myc. (a) There was no significant association between Wnt-1 expression and overall survival of patients (P>0.05); (b) The overall survival of patients with low Wnt-2 expression was obviously longer than that with high Wnt-2 expression (P<0.05); (c) There was a trend toward increased β-catenin expression with shorter survival of patients, but there was no statistical significance (P>0.05); (d) Brainstem glioma patients with low C-myc expression had a longer survival than that with high C-myc expression (P<0.05). (low-expression and high-expression group was scored as 0 or 1; 2, 3 or 4, respectively)

gliomas; thus, the biological features and mechanisms involved in the occurrence and development of brainstem gliomas are still unknown, which limit the progress of the clinical treatment of brainstem gliomas.

Wnt/β-catenin signaling pathway plays an important role in the regulation of cell growth and differentiation, embryonic development and the process of tumor occurrence and development. Abnormal activation of Wnt/β-catenin pathway is closely associated with the occurrence and development of many human tumors, such as colorectal tumors, lung cancers and liver cancers.10-12 In the central nervous system, Wnt/β-catenin signaling pathway is closely associated with the occurrence and development of medulloblastoma, which has been well studied.13 Additionally, related gene interference and targeted therapy are also being studied.14,15 The relationship between Wnt/β-catenin pathway and gliomas has been the focus of many biological studies in recent years.16-18 At present, it is not clear whether this pathway also plays a role in the occurrence and development of brainstem gliomas and whether it can be used as a new route for targeted therapy against brainstem gliomas.

As the initial proteins of Wnt/β-catenin signaling pathway, Wnt proteins are a group of secreted glycoproteins encoded by the Wnt gene. The Wnt gene plays an important role in cell differentiation, polarity, migration and proliferation. There are currently 19 known Wnt protein family members that play important autocrine or paracrine roles.19 Wnt-1 and Wnt-2 are the points of interest of present research among the Wnt family members. Our results show that Wnt-1 was not expressed in normal brain tissues but was expressed in some brainstem gliomas, which was consistent with the results of Liu et al,20 concerning the expression of gliomas in other locations. Wnt-2 was expressed in both normal brain tissue and brainstem gliomas; its expression in high-grade brainstem gliomas was significantly higher than that in low-grade gliomas and normal brain tissues. Pu et al used immunohistochemistry and reverse transcription polymerase chain reaction (RT-PCR) methods to detect Wnt-2 expression in gliomas and also obtained similar results; in addition, Wnt-2 knockout in human U251 glioma cells also inhibited cell proliferation and invasion and promoted cell apoptosis, indicating that Wnt-2 could be used as a potential target for glioma treatment.21

β-catenin is a multi-functional protein. When Wnt signaling is not activated, β-catenin interacts with E-cadherin to participate in cell adhesion; after Wnt signaling is activated, β-catenin phosphorylation and degradation are inhibited, and extra β-catenin accumulates in the cytoplasm and enters the nucleus to interact with transcription factors and induce the transcription of genes associated with cell proliferation. Therefore, β-catenin is a major molecule of Wnt/β-catenin signaling pathway. Sareddy et al studied 32 cases of different grades of supratentorial gliomas and showed that β-catenin expression in high-grade gliomas was significantly higher than that in low-grade gliomas and normal brain tissues. Our results show that β-catenin was expressed in the cytoplasm of brainstem gliomas, and the expression increased with increasing pathological grades; the abnormal expression of β-catenin indicated that the Wnt/β-catenin pathway might be activated. The expression of C-myc, as a downstream target gene in this pathway, was higher in brainstem gliomas than in normal brain tissues and its expression increased significantly with the elevation in malignancy among brainstem gliomas. In addition, we detected the expression of the proliferation-related gene, Ki-67, using immunohistochemistry. The results of the correlation analysis show that the expression of Ki-67 was positively correlated with the expressions of Wnt-2, β-catenin and C-myc, further indicating that Wnt/β-catenin signaling pathway might be activated to promote the expression of downstream target genes, thus resulting in abnormal cell proliferation and tumor occurrence and development. The specific mechanisms and methods of participation of Wnt/β-catenin signaling pathway in the occurrence and development of brainstem gliomas still require further in-depth studies.

At present, there is no evidence regarding the relationship between the Wnt/β-catenin signaling pathway and prognosis of brainstem glioma. Our study suggests that Wnt-1 and β-catenin expressions were not significantly associated with the overall survival of patients. However, there was a trend toward increased β-catenin expression with shorter survival. The survival of patients with a low-expression level of Wnt-2 and C-myc had significantly longer survival than the high-expression group. Because the subjects were limited in our group, the relationship between Wnt/β-catenin signaling pathway and prognosis of brainstem glioma needs to be validated in a larger patient cohort.

In summary, our study show that the expressions of Wnt/β-catenin signaling pathway-related components in brainstem gliomas were higher than in normal brain tissues. The
expressions of Wnt-2, β-catenin and C-myc were significantly correlated with the pathological grades of tumors. Wnt/β-catenin signaling pathway might be activated abnormally and was closely associated with the occurrence and development of brainstem gliomas. In addition, the expressions of Wnt-2, β-catenin and C-myc were associated with the prognosis of brainstem gliomas and may be used as prognostic marker. Finally, designing small molecular compounds or monoclonal antibodies to target this signaling pathway might be a promising therapeutic strategy for the treatment of brainstem gliomas.

ACKNOWLEDGEMENTS

This work was supported by the National Natural Science Foundation of China (No. 30772237 and 30900479), Capital Medical Development Foundation (No. 2009-1040) and Beijing Science and Technology New Star Program (No. 2010B121).

REFERENCES